A carregar...
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
The KRAS mutation remains the most common driver mutation in patients with non-small cell lung cancer (NSCLC) and confers a poor prognosis. Thus far, efforts to target this mutation over the last two decades have been unsuccessful. Over the past 5 years, many efforts to develop drugs that target the...
Na minha lista:
| Publicado no: | Clin Transl Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer Berlin Heidelberg
2015
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4678136/ https://ncbi.nlm.nih.gov/pubmed/26668062 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40169-015-0075-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|